Skip to content
value.today

Artax Biopharma, Inc.

Total raised
$54 M
6 rounds on record
Latest round
$19 M
Jul 2024
First round on record
Jul 2014
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Artax Biopharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2024$19 MNo. 6$10 to $50 million

Artax Biopharma, Inc.: Raise no. 6, Jul 2024

Investors in this round

30 investors had bought by the notice of May 5, 2026: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $19 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$3,500,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joe W. Suarez · Executive Officer
  • Maria W. Nichol · Executive Officer
  • Robert W. Armstrong, Ph.D. · Executive Officer, Director
  • Alan W. Walts · Director
  • Andre W. Hoekema · Director
  • Casper W. Breum · Director
  • Damia W. Tormo, Ph.D. · Director
  • Gino W. Santini · Director
  • Raj W. Parekh · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Armstrong, Ph.D., President & Chief Executive Officer. Newest notice filed May 5, 2026 (1 amendment). Read the notice at the SEC.

debt, optionsSEC
Dec 2021$26 MNo. 5$10 to $50 million

Artax Biopharma, Inc.: Raise no. 5, Dec 2021

Investors in this round

28 investors had bought by the notice of May 18, 2022: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph M. Lobacki · Executive Officer, Director
  • Alan E. Walts · Director
  • Casper E. Breum · Director
  • Damia M. Tormo, Ph.D. · Director
  • Gino M. Santini · Director
  • Raj E. Parekh · Director
  • Robert M. Armstrong, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph M. Lobacki, President and CEO. Newest notice filed May 18, 2022 (1 amendment). Read the notice at the SEC.

equitySEC
Feb 2021$2 MNo. 4$2 to $10 million

Artax Biopharma, Inc.: Raise no. 4, Feb 2021

Investors in this round

19 investors had bought by the notice of Feb 26, 2021: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph M. Lobacki · Executive Officer, Director
  • Alan E. Walts · Director
  • Damia M. Tormo · Director
  • Gino M. Santini · Director
  • Robert M. Armstrong, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph M. Lobacki, President and CEO. Newest notice filed Feb 26, 2021. Read the notice at the SEC.

debt, optionsSEC
Apr 2020$2 MNo. 3$2 to $10 million

Artax Biopharma, Inc.: Raise no. 3, Apr 2020

Investors in this round

9 investors had bought by the notice of May 4, 2020: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Massachusetts

People named in the notice

  • Joseph M. Lobacki · Executive Officer, Director
  • Alan E. Walts · Director
  • Damia M. Tormo, Ph.D. · Director
  • Gino M. Santini · Director
  • Javier M. Garcia · Director
  • Robert E. Armstrong, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph M. Lobacki, President and CEO. Newest notice filed May 4, 2020. Read the notice at the SEC.

equitySEC
Jul 2015$3 MNo. 2$2 to $10 million

Artax Biopharma, Inc.: Raise no. 2, Jul 2015

Investors in this round

29 investors had bought by the notice of Oct 27, 2015: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $10 M offered; $7 M still to sell
Smallest investment taken
$5,000
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$250,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Damia Tormo · Executive Officer, Director · President, CEO, Treasurer and Founder
  • Peter B. Finn · Executive Officer · Secretary
  • Gino W. Santini · Director
  • Henri W. Termeer · Director
  • Javier Garcia · Director
  • Raj W. Parekh · Director
  • Robert W. Armstrong, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Salaries”

Signed by Peter B. Finn, Secretary. Newest notice filed Oct 27, 2015. Read the notice at the SEC.

equitySEC
Jul 2014$2 MNo. 1$2 to $10 million

Artax Biopharma, Inc.: Raise no. 1, Jul 2014

Investors in this round

18 investors had bought by the notice of Nov 10, 2014: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$5,000
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$349,800 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Damia Tormo · Executive Officer, Director · President, CEO, Treasurer and Founder
  • Peter B. Finn · Executive Officer · Secretary
  • Gino W. Santini · Director
  • Jan W. de Vries, Ph.D. · Director
  • Javier Garcia · Director
  • Robert W. Armstrong, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Salaries”

Signed by Peter B. Finn, Secretary. Newest notice filed Nov 10, 2014. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Artax Biopharma, Inc. chose not to state its revenue in its newest notice of a funding round (May 2026).

    SEC Form D · May 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Artax Biopharma, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Artax Biopharma, Inc.
NameRoleNamed in
Joe W. SuarezExecutive officerMay 2026
Maria W. NicholExecutive officerMay 2026
Robert W. Armstrong, Ph.D.Executive officerMay 2026
Joseph M. LobackiExecutive officerMay 2022
Damia TormoPresident, CEO, Treasurer and FounderOct 2015
Peter B. FinnSecretaryOct 2015
Alan W. WaltsDirectorMay 2026
Andre W. HoekemaDirectorMay 2026
Casper W. BreumDirectorMay 2026
Damia W. Tormo, Ph.D.DirectorMay 2026
Gino W. SantiniDirectorMay 2026
Raj W. ParekhDirectorMay 2026
Robert W. Armstrong, Ph.D.DirectorMay 2026
Alan E. WaltsDirectorMay 2022
Casper E. BreumDirectorMay 2022
Damia M. Tormo, Ph.D.DirectorMay 2022
Gino M. SantiniDirectorMay 2022
Joseph M. LobackiDirectorMay 2022
Raj E. ParekhDirectorMay 2022
Robert M. Armstrong, Ph.D.DirectorMay 2022
Damia M. TormoDirectorFeb 2021
Javier M. GarciaDirectorMay 2020
Robert E. Armstrong, Ph.D.DirectorMay 2020
Damia TormoPresident, CEO, Treasurer and FounderOct 2015
Henri W. TermeerDirectorOct 2015
Javier GarciaDirectorOct 2015
Jan W. de Vries, Ph.D.DirectorNov 2014